Hunter Associates Investment Management LLC Sells 908 Shares of ResMed Inc. (NYSE:RMD)

Hunter Associates Investment Management LLC lessened its holdings in ResMed Inc. (NYSE:RMDFree Report) by 1.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 50,388 shares of the medical equipment provider’s stock after selling 908 shares during the period. ResMed makes up approximately 1.6% of Hunter Associates Investment Management LLC’s holdings, making the stock its 12th biggest holding. Hunter Associates Investment Management LLC’s holdings in ResMed were worth $8,667,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of RMD. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of ResMed by 13.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 45,231 shares of the medical equipment provider’s stock worth $7,781,000 after buying an additional 5,517 shares during the period. Vaughan David Investments LLC IL purchased a new stake in shares of ResMed during the 4th quarter worth $29,322,000. International Assets Investment Management LLC lifted its stake in shares of ResMed by 11,960.3% during the 4th quarter. International Assets Investment Management LLC now owns 22,191 shares of the medical equipment provider’s stock worth $3,817,000 after purchasing an additional 22,007 shares during the last quarter. Synergy Asset Management LLC lifted its stake in shares of ResMed by 29.2% during the 4th quarter. Synergy Asset Management LLC now owns 69,383 shares of the medical equipment provider’s stock worth $11,935,000 after purchasing an additional 15,663 shares during the last quarter. Finally, Inspire Advisors LLC lifted its stake in shares of ResMed by 20.2% during the 3rd quarter. Inspire Advisors LLC now owns 1,553 shares of the medical equipment provider’s stock worth $230,000 after purchasing an additional 261 shares during the last quarter. Institutional investors own 54.98% of the company’s stock.

ResMed Stock Up 0.7 %

Shares of RMD stock opened at $178.85 on Friday. The stock’s 50-day simple moving average is $186.18 and its 200-day simple moving average is $170.63. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.89 and a current ratio of 3.11. The firm has a market capitalization of $26.31 billion, a PE ratio of 29.56, a P/E/G ratio of 2.19 and a beta of 0.67. ResMed Inc. has a fifty-two week low of $132.24 and a fifty-two week high of $243.52.

ResMed (NYSE:RMDGet Free Report) last announced its quarterly earnings data on Wednesday, January 24th. The medical equipment provider reported $1.88 earnings per share for the quarter, beating analysts’ consensus estimates of $1.81 by $0.07. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.15 billion. ResMed had a return on equity of 23.86% and a net margin of 19.77%. The company’s revenue was up 12.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.66 earnings per share. Equities analysts expect that ResMed Inc. will post 7.47 earnings per share for the current year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Thursday, February 8th were issued a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a dividend yield of 1.07%. The ex-dividend date of this dividend was Wednesday, February 7th. ResMed’s dividend payout ratio is presently 31.74%.

Analyst Upgrades and Downgrades

RMD has been the subject of a number of analyst reports. UBS Group upped their price objective on ResMed from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Mizuho restated a “buy” rating and set a $215.00 price objective on shares of ResMed in a research note on Wednesday, March 27th. Royal Bank of Canada upped their price objective on ResMed from $181.00 to $182.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 25th. KeyCorp initiated coverage on ResMed in a research note on Tuesday, February 6th. They set an “overweight” rating and a $227.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their target price on ResMed from $160.00 to $195.00 and gave the company an “overweight” rating in a research report on Tuesday, January 9th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $199.20.

Get Our Latest Stock Analysis on RMD

Insider Activity

In related news, Director Peter C. Farrell sold 10,935 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the sale, the director now directly owns 157,404 shares of the company’s stock, valued at $28,751,414.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, General Counsel Michael J. Rider sold 200 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $173.25, for a total transaction of $34,650.00. Following the sale, the general counsel now directly owns 6,688 shares of the company’s stock, valued at $1,158,696. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 10,935 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the sale, the director now directly owns 157,404 shares in the company, valued at $28,751,414.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,216 shares of company stock valued at $2,046,617. Company insiders own 1.21% of the company’s stock.

About ResMed

(Free Report)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Read More

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMDFree Report).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.